We propose to facilitate analysis of nervous system tumors in this group effort by providing centralized mouse pathology services, taking advantage of local expertise in mouse perfusion and analysis of mouse nerve and brain tumors. This Core facility will use components of a highly successful core laboratory located within the Department of Pathology at Cincinnati Children's Hospital for paraffin embedding, plastic embedding for EM and electron microscope beam time. The pathology core will serve as an essential component for the research activities at Cincinnati Children's Hospital and will provide services to 3 investigators from Cincinnati Children's Hospital, University of Cincinnati Genomic research Institute (GRI),and University of Minnesota.
The specific aims of this core are to 1) provide investigators assistance in tissue based approaches for nerve histology, immunohistochemistry, and electron microscopy;2) provide pathologic support for non-perfused tissue such as tumors from xenografts, with support from human pathologists.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS057531-05
Application #
8382458
Study Section
Special Emphasis Panel (ZNS1-SRB-G)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2012
Total Cost
$106,581
Indirect Cost
$35,528
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
Wu, Jianqiang; Keng, Vincent W; Patmore, Deanna M et al. (2016) Insertional Mutagenesis Identifies a STAT3/Arid1b/?-catenin Pathway Driving Neurofibroma Initiation. Cell Rep 14:1979-90
Jousma, Edwin; Rizvi, Tilat A; Wu, Jianqiang et al. (2015) Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer 62:1709-16
Haworth, Kellie B; Leddon, Jennifer L; Chen, Chun-Yu et al. (2015) Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer 62:571-6
Wu, J; Patmore, D M; Jousma, E et al. (2014) EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 33:173-80
Watson, Adrienne L; Anderson, Leah K; Greeley, Andrew D et al. (2014) Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget 5:1502-14
Moriarity, Branden S; Rahrmann, Eric P; Beckmann, Dominic A et al. (2014) Simple and efficient methods for enrichment and isolation of endonuclease modified cells. PLoS One 9:e96114
Brundage, M E; Tandon, P; Eaves, D W et al. (2014) MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene 33:5626-36
Rahrmann, Eric P; Watson, Adrienne L; Keng, Vincent W et al. (2013) Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet 45:756-66
Prada, Carlos E; Jousma, Edwin; Rizvi, Tilat A et al. (2013) Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol 125:159-68

Showing the most recent 10 out of 21 publications